Menu

New-Generation Incubator Brings the Latest Technology to Mid-Capacity Microplate Cell Culture

New Thermo Scientific Cytomat 2 C-LiN Series Automated Incubator delivers robust and reliable culture solution for cell-based pharmaceutical applications

Jun 26, 2019
Thermo Fisher Scientific

As the pharmaceutical industry continues to increase its focus on the development of biologics, scientists require robust, automation-ready incubation solutions with the reliability and flexibility to support a range of discovery, development and processing applications for future cell-based and cell-derived medicines.

Underpinned by over 50 years of experience in advanced environmental chamber and incubation technology, the Thermo Scientific Cytomat 2 C-LiN Series Automated Incubator provides research scientists and cell culture biologists in the pharmaceutical industry with an automation-ready, mid-capacity cell culture solution. The new automated incubator system delivers cell growth and environmental control across a range of microplate applications, including cell-based screening, immuno-capture assays, microbiology and enzyme testing. Designed for fast and flexible integration, the Cytomat 2 C-LiN Series Automated Incubator enhances laboratory automation installations.

Thermo Fisher Scientific is showcasing its new generation of automated incubators during the 2019 European conference and exhibition of the Society for Laboratory Automation and Screening (SLAS Europe) being held June 26–28, Booth #418 at the Centre de Convencions Internacional, Barcelona, Spain.

"With the increasing number of biotherapeutics in development and their ever-growing complexity, scientists need cell culture solutions they can trust to deliver dependable cellular growth within a controlled and contamination-free environment," said Hansjoerg Haas, senior director and general manager, laboratory automation, Thermo Fisher Scientific. "The launch of the Cytomat 2 C-LiN Series Automated Incubator brings the latest automation-ready incubation technology to mid-capacity microplate applications, enabling scientists to more easily sustain valuable and vital cell lines for the synthesis and development of future therapeutics."

The Cytomat 2 C-LiN Series Automated Incubator provides research scientists and cell culture biologists with: 

  • Controlled humidity through the optional Hydra Smart ultrasonic vaporizer and easy-to-fill external water tank, which removes the need to open the system to maintain water stocks, protecting cells from fluctuating environmental conditions.
  • Reduced risk of contamination through an optional solid copper chamber, as well as a built-in ContraCon automatic decontamination routine, which employs a combination of heat and high humidity.
  • Flexible integration possibilities for quick and easy configuration into laboratory automation platforms via multiple gate positions.
  • A new, quick plate shuttle system design with a mean access time of 12 seconds.
  • A versatile cell culture solution that supports the growth and maintenance of stem, primary, immortalized and organoid cell lines.


July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.